6903-14-6

Basic information

• Product Name: Benzene, 1-(benzyloxy)-4-(2-propynyloxy)- (7CI,8CI)
• Synonyms: Benzene, 1-(benzyloxy)-4-(2-propynyloxy)- (7CI,8CI);Benzene, 1-(benzyloxy)-4-(2-propynyloxy)-;1-(phenylMethoxy)-4-(2-propyn-1-yloxy)-;1-phenylmethoxy-4-prop-2-ynoxybenzene
• CAS NO: 6903-14-6
• Molecular Formula: C₁₆H₁₄O₂
• Molecular Weight: 238.28
• Mol File: 6903-14-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzene, 1-(benzyloxy)-4-(2-propynyloxy)- (7CI,8CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(benzyloxy)-4-(2-propynyloxy)- (7CI,8CI)(6903-14-6)
• EPA Substance Registry System: Benzene, 1-(benzyloxy)-4-(2-propynyloxy)- (7CI,8CI)(6903-14-6)

Safety Data

• Hazardous Substances Data: 6903-14-6(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 103-16-2 4-Benzyloxyphenol 
• 624-65-7 2-propynyl chloride 
• 106-96-7 propargyl bromide 

Downstream Products

• 34596-27-5 4-(prop-2-yn-1-yloxy)phenol 
• 103-16-2 4-Benzyloxyphenol 
• 1374456-93-5 6-(benzyloxy)chroman-3-one 

Relevant articles and documents

Synthesis, biophysical characterization, and anti-HIV-1 fusion activity of DNA helix-based inhibitors with a p-benzyloxyphenyl substituent at the 5′-nucleobase site

DNA helix-based HIV-1 fusion inhibitors have been discovered as potent drug candidates. Introduction of hydrophobic groups to a nucleobase provides an opportunity to design inhibitors with novel structures and mechanisms of action. In this work, two novel nucleoside analogues (1 and 2) were synthesized and incorporated into four DNA duplex- and quadruplex-based inhibitors. All the molecules showed anti-HIV-1 fusion activity. The effect of the p-benzyloxyphenyl group and the attached linker on the helix formation and thermal stability were fully compared and discussed. Surface plasmon resonance analysis further indicated that inhibitors with the same DNA helix may still have variable reaction targets, mainly attributed to the different hydrophobic modifications.

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

A hierarchy of aryloxide deprotection by boron tribromide

Aryl propargyl ethers and esters are cleaved selectively in the presence of aryl methyl ethers and esters by boron tribromide in dichloromethane. Under the same conditions, allyl ethers undergo very rapid Claisen rearrangement, and benzyl ethers are also cleaved more rapidly than propargyl. A mechanism involving intramolecular delivery of bromide to the propargyl terminus is proposed.